Dr Abhishek Maiti speaks to ecancer in an online interview for the virtual ASH 2021 meeting about updated outcomes in genomic subgroups from a phase II trial of ten-day decitabine with venetoclax (DEC10-VEN) in acute myeloid leukaemia (AML).

He explains the background of this update, which found DEC10-VEN to offer better outcomes compared to intensive chemotherapy in older patients with newly diagnosed or relapsed/refractory AML.

Dr Maiti reports outcomes across various genomic subgroups, some of which were favourable while others were suboptimal.